A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma

Few effective treatment options are available for patients with advanced or metastatic urothelial carcinoma (UC) after unsuccessful first-line platinum-based chemotherapy. To date, immune checkpoint inhibitors are novel therapeutic agents for UC treatment. From May 2016 to May 2017, five anti-PD-1/P...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Fu-Shun, Su, Chun-Hung, Huang, Kou-How
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742464/
https://www.ncbi.nlm.nih.gov/pubmed/29376081
http://dx.doi.org/10.1155/2017/6940546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742464/
https://www.ncbi.nlm.nih.gov/pubmed/29376081
http://dx.doi.org/10.1155/2017/6940546

Ejemplares similares